《新股表現》心泰醫療(02291.HK)高開2.2%報29.8元
心泰醫療(02291.HK)暗盤高見31元,收29.25元,高上市價0.3%;該股今日首掛開市報29.8元,較發售定價29.15元高2.23%,市前成交55.6萬股。
樂普心泰是內地結構性心臟病介入醫療器械供應商,擁有跨越逾廿年往績記錄。是次來港上市共發售售2,245.5萬股,並已引入包括嘉實國際旗下Harvest、臨港控股(600848.SH)全資附屬臨港及九州通醫藥(600998.SH)全資附屬Jointown International等三名基石投資者,合共認購667.6萬股;其中10%公開發售獲1.1倍超購,人人有份;股份以招股範圍(29.15-31.45元)下限定價,料集資淨額約5.67億元,主要用作未來五年研發、銷售和營銷活動、提升產能和加強製造能力,以及潛在戰略投資和收購提供資金等。上市獨家保薦人中金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.